Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813929 | 0.74 | HCAR2 (0.36) | GRM4CYP1A2 | |
| SCHEMBL545813 | 0.67 | GRM4 (0.39) | GRM4 | |
| SCHEMBL30132904 | 0.67 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL473498 | 0.67 | GRM4 (0.39) | GRM4 | |
| SCHEMBL421235 | 0.67 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL352379 | 0.67 | GRM4 (0.39) | GRM4 | |
| SCHEMBL473390 | 0.67 | GRM4 (0.46) | GRM4 | |
| SCHEMBL2619233 | 0.67 | GRM4 (0.39) | GRM4CYP1A2 | |
| SCHEMBL11874314 | 0.67 | GRM4 (0.39) | GRM4 | |
| SCHEMBL29414359 | 0.67 | GRM4 (0.39) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247031-B2 | Cyclobutyl pyrazolopyrimidine PDE9 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3893881-B1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3893881-A4 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247031-B2 | Cyclobutyl pyrazolopyrimidine PDE9 inhibitors | PDE9A, PDE5A, PDE3B | GRM4 528/4885CYP1A2 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.